{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:47:17Z","timestamp":1795085237261,"version":"4.10.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cluster of Excellence iFIT (EXC 2180) \"Image Guided and Functionally Instructed Tumor Therapies, Germany"},{"name":"Werner Siemens Foundation"},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors have revolutionized cancer therapy, yet the efficacy of these treatments is often limited by the heterogeneous and hypoxic tumor microenvironment (TME) of solid tumors. In the TME, programmed death-ligand 1 (PD-L1) expression on cancer cells is mainly regulated by Interferon-gamma (IFN-\u03b3), which induces T cell exhaustion and enables tumor immune evasion. In this study, we demonstrate that acidosis, a common characteristic of solid tumors, significantly increases IFN-\u03b3-induced PD-L1 expression on aggressive cancer cells, thus promoting immune escape. Using preclinical models, we found that acidosis enhances the genomic expression and phosphorylation of signal transducer and activator of transcription 1 (STAT1), and the translation of STAT1 mRNA by eukaryotic initiation factor 4F (elF4F), resulting in an increased PD-L1 expression. We observed this effect in murine and human anti-PD-L1-responsive tumor cell lines, but not in anti-PD-L1-nonresponsive tumor cell lines. In vivo studies fully validated our in vitro findings and revealed that neutralizing the acidic extracellular tumor pH by sodium bicarbonate treatment suppresses IFN-\u03b3-induced PD-L1 expression and promotes immune cell infiltration in responsive tumors and thus reduces tumor growth. However, this effect was not observed in anti-PD-L1-nonresponsive tumors. In vivo experiments in tumor-bearing IFN-\u03b3\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice validated the dependency on immune cell-derived IFN-\u03b3 for acidosis-mediated cancer cell PD-L1 induction and tumor immune escape. Thus, acidosis and IFN-\u03b3-induced elevation of PD-L1 expression on cancer cells represent a previously unknown immune escape mechanism that may serve as a novel biomarker for anti-PD-L1\/PD-1 treatment response. These findings have important implications for the development of new strategies to enhance the efficacy of immunotherapy in cancer patients.\n                  <\/jats:p>","DOI":"10.1186\/s12943-023-01900-0","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T04:02:29Z","timestamp":1702612949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors"],"prefix":"10.1186","volume":"22","author":[{"given":"Philipp","family":"Knopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Stowbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina H. L.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Poxleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bredi","family":"Tako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Sonanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Krishnamachary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanhita","family":"Sinharay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonzalez-Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Reckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bomze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Forchhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaver M.","family":"Bhujwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke F.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 F.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd J.","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Kneilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"4","key":"1900_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol"},{"issue":"8","key":"1900_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41388-020-01611-6","volume":"40","author":"JE Grossman","year":"2021","unstructured":"Grossman JE, et al. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021;40(8):1393\u20135.","journal-title":"Oncogene"},{"issue":"6","key":"1900_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2112187","volume":"386","author":"KS Tewari","year":"2022","unstructured":"Tewari KS, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med. 2022;386(6):544\u201355.","journal-title":"N Engl J Med"},{"issue":"17","key":"1900_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557\u201368.","journal-title":"N Engl J Med"},{"issue":"23","key":"1900_CR5","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145\u201358.","journal-title":"N Engl J Med"},{"issue":"6382","key":"1900_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"4","key":"1900_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, et al. T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1900_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"1900_CR9","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377.","journal-title":"Blood"},{"issue":"6","key":"1900_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47(6):1083\u20131099.e6.","journal-title":"Immunity"},{"issue":"1","key":"1900_CR11","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8(1):14572.","journal-title":"Nat Commun"},{"issue":"4","key":"1900_CR12","doi-asserted-by":"publisher","first-page":"e1294299","DOI":"10.1080\/2162402X.2017.1294299","volume":"6","author":"JW Kleinovink","year":"2017","unstructured":"Kleinovink JW, et al. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology. 2017;6(4):e1294299.","journal-title":"Oncoimmunology"},{"issue":"2","key":"1900_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5(2):106\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"1900_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201.","journal-title":"Cell Rep"},{"issue":"5","key":"1900_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"13","key":"1900_CR16","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1084\/jem.20161462","volume":"213","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213(13):2835\u201340.","journal-title":"J Exp Med"},{"issue":"1","key":"1900_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41467-020-14290-4","volume":"11","author":"JB Williams","year":"2020","unstructured":"Williams JB, et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-\u03b3-signaling mutant cancer cells. Nat Commun. 2020;11(1):602.","journal-title":"Nat Commun"},{"issue":"7528","key":"1900_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"10","key":"1900_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O. Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer. 2017;17(10):577\u201393.","journal-title":"Nat Rev Cancer"},{"key":"1900_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2017.03.001","volume":"43","author":"V Huber","year":"2017","unstructured":"Huber V, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol. 2017;43:74\u201389.","journal-title":"Semin Cancer Biol"},{"issue":"42","key":"1900_CR21","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/onc.2017.188","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng J, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene. 2017;36(42):5829\u201339.","journal-title":"Oncogene"},{"issue":"4","key":"1900_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/cancers11040450","volume":"11","author":"S Daneshmandi","year":"2019","unstructured":"Daneshmandi S, Wegiel B, Seth P. Blockade of Lactate Dehydrogenase-A (LDH-A) improves efficacy of anti-programmed cell death-1 (PD-1) therapy in melanoma. Cancers (Basel). 2019;11(4):450.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1900_CR23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1186\/s12885-022-09956-9","volume":"22","author":"Y-J Kwon","year":"2022","unstructured":"Kwon Y-J, et al. The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells. BMC Cancer. 2022;22(1):852.","journal-title":"BMC Cancer"},{"issue":"6","key":"1900_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas S, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76(6):1381\u201390.","journal-title":"Cancer Res"},{"issue":"3","key":"1900_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/imm.12917","volume":"154","author":"S Damgaci","year":"2018","unstructured":"Damgaci S, et al. Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology. 2018;154(3):354\u201362.","journal-title":"Immunology"},{"issue":"9","key":"1900_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-019-1299-4","volume":"36","author":"A Giatromanolaki","year":"2019","unstructured":"Giatromanolaki A, et al. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Med Oncol. 2019;36(9):76.","journal-title":"Med Oncol"},{"issue":"5","key":"1900_CR27","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","volume":"73","author":"V Estrella","year":"2013","unstructured":"Estrella V, et al. Acidity generated by the tumor microenvironment drives local invasion. Can Res. 2013;73(5):1524\u201335.","journal-title":"Can Res"},{"issue":"1","key":"1900_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1900_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"issue":"1","key":"1900_CR30","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11(1):4835.","journal-title":"Nat Commun"},{"issue":"18","key":"1900_CR31","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1002\/cam4.4190","volume":"10","author":"L Ding","year":"2021","unstructured":"Ding L, et al. PD-1\/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: mechanisms affecting efficacy and combination therapies. Cancer Med. 2021;10(18):6384\u2013401.","journal-title":"Cancer Med"},{"key":"1900_CR32","doi-asserted-by":"publisher","first-page":"114646","DOI":"10.1016\/j.biopha.2023.114646","volume":"162","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J, Kharazinejad E. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. Biomed Pharmacother. 2023;162:114646.","journal-title":"Biomed Pharmacother"},{"issue":"5102","key":"1900_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1126\/science.8456300","volume":"259","author":"DK Dalton","year":"1993","unstructured":"Dalton DK, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993;259(5102):1739\u201342.","journal-title":"Science"},{"issue":"2","key":"1900_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/mrm.22637","volume":"65","author":"T Shah","year":"2011","unstructured":"Shah T, et al. CEST-FISP: a novel technique for rapid chemical exchange saturation transfer MRI at 7 T. Magn Reson Med. 2011;65(2):432\u20137.","journal-title":"Magn Reson Med"},{"key":"1900_CR35","first-page":"97855154","volume":"9788","author":"KM Jones","year":"2016","unstructured":"Jones KM, et al. Respiration gating and Bloch fitting improve pH measurements with acidoCEST MRI in an ovarian orthotopic tumor model. Proc SPIE Int Soc Opt Eng. 2016;9788:97855154.","journal-title":"Proc SPIE Int Soc Opt Eng"},{"issue":"7","key":"1900_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1541-7786.MCR-10-0449","volume":"9","author":"T Nishisho","year":"2011","unstructured":"Nishisho T, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011;9(7):845\u201355.","journal-title":"Mol Cancer Res"},{"issue":"8","key":"1900_CR37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2967\/jnumed.109.068981","volume":"51","author":"X Zhang","year":"2010","unstructured":"Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med. 2010;51(8):1167\u201370.","journal-title":"J Nucl Med"},{"issue":"1","key":"1900_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","volume":"5","author":"SI Mosely","year":"2017","unstructured":"Mosely SI, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res. 2017;5(1):29\u201341.","journal-title":"Cancer Immunol Res"},{"issue":"7516","key":"1900_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature13485","volume":"513","author":"AL Wolfe","year":"2014","unstructured":"Wolfe AL, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014;513(7516):65\u201370.","journal-title":"Nature"},{"issue":"12","key":"1900_CR40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41591-018-0217-1","volume":"24","author":"M Cerezo","year":"2018","unstructured":"Cerezo M, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018;24(12):1877\u201386.","journal-title":"Nat Med"},{"issue":"11","key":"1900_CR41","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1073\/pnas.95.11.6067","volume":"95","author":"PJ Lopez","year":"1998","unstructured":"Lopez PJ, et al. Translation inhibitors stabilize Escherichia coli mRNAs independently of ribosome protection. Proc Natl Acad Sci U S A. 1998;95(11):6067\u201372.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1900_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"issue":"9","key":"1900_CR43","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812\u20139.","journal-title":"Blood"},{"issue":"3","key":"1900_CR44","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.4049\/jimmunol.0902584","volume":"184","author":"K Dietl","year":"2010","unstructured":"Dietl K, et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol. 2010;184(3):1200\u20139.","journal-title":"J Immunol"},{"issue":"6","key":"1900_CR45","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.immuni.2012.03.024","volume":"36","author":"K Hirahara","year":"2012","unstructured":"Hirahara K, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity. 2012;36(6):1017\u201330.","journal-title":"Immunity"},{"issue":"6","key":"1900_CR46","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1158\/0008-5472.CAN-07-5575","volume":"69","author":"IF Robey","year":"2009","unstructured":"Robey IF, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009;69(6):2260\u20138.","journal-title":"Cancer Res"},{"issue":"5","key":"1900_CR47","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/mrm.25053","volume":"72","author":"LQ Chen","year":"2014","unstructured":"Chen LQ, et al. Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI. Magn Reson Med. 2014;72(5):1408\u201317.","journal-title":"Magn Reson Med"},{"issue":"12","key":"1900_CR48","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s43018-022-00470-2","volume":"3","author":"F Cappellesso","year":"2022","unstructured":"Cappellesso F, et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer. 2022;3(12):1464\u201383.","journal-title":"Nat Cancer"},{"issue":"1","key":"1900_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-016-0562-y","volume":"15","author":"S Faes","year":"2016","unstructured":"Faes S, et al. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors. Mol Cancer. 2016;15(1):78.","journal-title":"Mol Cancer"},{"issue":"8","key":"1900_CR50","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/0284186X.2019.1598575","volume":"58","author":"L Reiniger","year":"2019","unstructured":"Reiniger L, et al. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. Acta Oncol. 2019;58(8):1087\u201394.","journal-title":"Acta Oncol"},{"issue":"9","key":"1900_CR51","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/ijc.30646","volume":"140","author":"J P\u00f6tzl","year":"2017","unstructured":"P\u00f6tzl J, et al. Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-\u03b3 and induces NK cell-dependent lymphoma control without other immunotherapies. Int J Cancer. 2017;140(9):2125\u201333.","journal-title":"Int J Cancer"},{"issue":"2","key":"1900_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/PL00007593","volume":"176","author":"A Bidani","year":"1998","unstructured":"Bidani A, et al. Evidence for pH sensitivity of tumor necrosis factor-alpha release by alveolar macrophages. Lung. 1998;176(2):111\u201321.","journal-title":"Lung"},{"issue":"4","key":"1900_CR53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00262-017-1955-5","volume":"66","author":"G Hartley","year":"2017","unstructured":"Hartley G, et al. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-\u03b1. Cancer Immunol Immunother. 2017;66(4):523\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"1900_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","volume":"33","author":"VL Payen","year":"2020","unstructured":"Payen VL, et al. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48\u201366.","journal-title":"Mol Metab"},{"issue":"5","key":"1900_CR55","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1159\/000343315","volume":"30","author":"S Hosogi","year":"2012","unstructured":"Hosogi S, et al. An inhibitor of Na(+)\/H(+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl(-) concentration via DIDS-sensitive pathways. Cell Physiol Biochem. 2012;30(5):1241\u201353.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"1900_CR56","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3390\/molecules20022323","volume":"20","author":"BP Mahon","year":"2015","unstructured":"Mahon BP, Pinard MA, McKenna R. Targeting carbonic anhydrase IX activity and expression. Molecules. 2015;20(2):2323\u201348.","journal-title":"Molecules"},{"issue":"7","key":"1900_CR57","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1039\/C4NP00006D","volume":"31","author":"L Pan","year":"2014","unstructured":"Pan L, et al. Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species. Nat Prod Rep. 2014;31(7):924\u201339.","journal-title":"Nat Prod Rep"},{"issue":"4","key":"1900_CR58","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895\u2013904.","journal-title":"J Exp Med"},{"issue":"1","key":"1900_CR59","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1038\/s41598-022-07153-z","volume":"12","author":"Y Jin","year":"2022","unstructured":"Jin Y, et al. Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment. Sci Rep. 2022;12(1):3278.","journal-title":"Sci Rep"},{"issue":"1","key":"1900_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13550-018-0433-1","volume":"8","author":"M Tomita","year":"2018","unstructured":"Tomita M, et al. Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Res. 2018;8(1):82.","journal-title":"EJNMMI Res"},{"issue":"734853","key":"1900_CR61","first-page":"11","volume":"11","author":"X Zheng","year":"2021","unstructured":"Zheng X, et al. Disulfiram improves the Anti-PD-1 therapy efficacy by regulating PD-L1 expression via epigenetically reactivation of IRF7 in triple negative breast cancer. Front Oncol. 2021;11(734853):11.","journal-title":"Front Oncol"},{"issue":"7637","key":"1900_CR62","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"16","key":"1900_CR63","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","volume":"24","author":"BW Higgs","year":"2018","unstructured":"Higgs BW, et al. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin Cancer Res. 2018;24(16):3857\u201366.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1900_CR64","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-18-0309","volume":"24","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, et al. Quantitative spatial profiling of PD-1\/PD-L1 Interaction and HLA-DR\/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin Cancer Res. 2018;24(21):5250\u201360.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1900_CR65","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/1521-4141(200109)31:9<2829::AID-IMMU2829>3.0.CO;2-U","volume":"31","author":"M Bosticardo","year":"2001","unstructured":"Bosticardo M, et al. Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7\/CD28 costimulation. Eur J Immunol. 2001;31(9):2829\u201338.","journal-title":"Eur J Immunol"},{"issue":"11","key":"1900_CR66","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72(11):2746\u201356.","journal-title":"Cancer Res"},{"issue":"7","key":"1900_CR67","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41416-019-0542-2","volume":"121","author":"A El-Kenawi","year":"2019","unstructured":"El-Kenawi A, et al. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Br J Cancer. 2019;121(7):556\u201366.","journal-title":"Br J Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01900-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T05:06:41Z","timestamp":1702616801000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01900-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01900-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2816652\/v1","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>Study approval<\/b>All animal experiments were approved by the Regierungspr\u00e4sidium T\u00fcbingen and were in concordance with German federal regulations. The veterinarians at the University of T\u00fcbingen were consulted for conducting in vivo animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}